WS
SEEL

Wedbush Securities’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Wedbush Securities’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-21
Closed -$75K – 1044
2019
Q3 		$75K Buy
21
+17
+425% +$102K 0.01% 916
2019
Q2 		$35K Buy
+4
New +$42.1K ﹤0.01% 962

Other funds holding SEEL

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
MWP
MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Wedbush Securities's SEEL Position: Q4 2019 in Review

Wedbush Securities sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2019, closing a stake of 21 shares — an estimated $75K sold.

Wedbush Securities first reported a position in SEEL in Q2 2019 and held it in 2 quarters. The position peaked at $75K in Q3 2019. 13 funds tracked by Wall St. Rank hold SEEL as of Q4 2019.

  • Wedbush Securities reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Wedbush Securities sold 21 Seelos Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $75K.
  • Wedbush Securities first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • Wedbush Securities's Seelos Therapeutics, Inc. Common Stock position peaked at $75K in Q3 2019.
  • 13 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Wedbush Securities's 13F filing for Q4 2019, filed 16 Jan 2020.